PL2102331T3 - Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+ - Google Patents
Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+Info
- Publication number
- PL2102331T3 PL2102331T3 PL08701232T PL08701232T PL2102331T3 PL 2102331 T3 PL2102331 T3 PL 2102331T3 PL 08701232 T PL08701232 T PL 08701232T PL 08701232 T PL08701232 T PL 08701232T PL 2102331 T3 PL2102331 T3 PL 2102331T3
- Authority
- PL
- Poland
- Prior art keywords
- normal
- cells
- composition
- lymphoid cells
- lymphocytes
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000004698 lymphocyte Anatomy 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 210000001550 testis Anatomy 0.000 abstract 2
- 230000035131 DNA demethylation Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
| EP08701232A EP2102331B1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cd4+ cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2102331T3 true PL2102331T3 (pl) | 2012-01-31 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08701232T PL2102331T3 (pl) | 2007-01-03 | 2008-01-03 | Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (enExample) |
| EP (1) | EP2102331B1 (enExample) |
| JP (1) | JP5452231B2 (enExample) |
| AT (1) | ATE522600T1 (enExample) |
| AU (1) | AU2008203730B2 (enExample) |
| CY (1) | CY1112668T1 (enExample) |
| DK (1) | DK2102331T3 (enExample) |
| ES (1) | ES2372713T3 (enExample) |
| GB (1) | GB0700058D0 (enExample) |
| HR (1) | HRP20110899T1 (enExample) |
| PL (1) | PL2102331T3 (enExample) |
| PT (1) | PT2102331E (enExample) |
| SI (1) | SI2102331T1 (enExample) |
| WO (1) | WO2008081035A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8467973B2 (en) | 2009-07-28 | 2013-06-18 | Promising Future, Llc | Pairing processes for preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| US9211321B2 (en) | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| KR20230005428A (ko) | 2015-05-28 | 2023-01-09 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 진단 방법 |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| EP3583129B1 (en) | 2017-02-14 | 2021-11-03 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| KR20190130024A (ko) | 2017-04-03 | 2019-11-20 | 카이트 파마 인코포레이티드 | 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료 |
| BR102018008260A2 (pt) | 2017-04-24 | 2020-04-28 | Kite Pharma, Inc. | domínios de ligação ao antígeno humanizado e métodos de uso |
| US12097218B2 (en) | 2017-05-26 | 2024-09-24 | Kite Pharma, Inc. | Methods of making and using embryonic mesenchymal progenitor cells |
| CN111315403A (zh) | 2017-09-15 | 2020-06-19 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| EP3697500A1 (en) | 2017-10-18 | 2020-08-26 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| AU2019206724A1 (en) | 2018-01-15 | 2020-07-16 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist |
| WO2019152957A1 (en) | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| CA3090793C (en) | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| CN119656304A (zh) | 2018-04-12 | 2025-03-21 | 凯德药业股份有限公司 | 使用肿瘤微环境的特征的嵌合受体t细胞治疗 |
| KR102734592B1 (ko) | 2018-06-01 | 2024-11-27 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210155941A1 (en) | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| AU2019314452B2 (en) | 2018-08-02 | 2022-12-08 | Kite Pharma, Inc | Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| WO2020208054A1 (en) | 2019-04-12 | 2020-10-15 | Cytovac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| CN114206346A (zh) | 2019-05-03 | 2022-03-18 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| CN114391021B (zh) | 2019-06-21 | 2026-01-16 | 凯德药业股份有限公司 | TGF-β受体和使用方法 |
| WO2021046134A1 (en) | 2019-09-03 | 2021-03-11 | Allogene Therapeutics, Inc. | Methods of preparing t cells for t cell therapy |
| IL292665B2 (en) | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| WO2021168375A1 (en) | 2020-02-20 | 2021-08-26 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| EP4501951A3 (en) | 2020-08-25 | 2025-04-30 | Kite Pharma, Inc. | T cells with improved functionality |
| AU2021369507B2 (en) | 2020-10-28 | 2025-06-26 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| WO2022140159A1 (en) | 2020-12-24 | 2022-06-30 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| WO2022150582A1 (en) | 2021-01-10 | 2022-07-14 | Kite Pharma, Inc. | T cell therapy |
| EP4281545A1 (en) | 2021-01-21 | 2023-11-29 | CytoVac A/S | Method for t-cell expansion and related medical applications |
| JP2024507199A (ja) | 2021-02-20 | 2024-02-16 | カイト ファーマ インコーポレイテッド | 免疫療法を選択するための遺伝子マーカー |
| KR20230155521A (ko) | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| US12337035B2 (en) | 2021-04-16 | 2025-06-24 | Kite Pharma, Inc. | TACI binding molecules |
| EP4323943A1 (en) | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| KR20230173179A (ko) | 2021-05-14 | 2023-12-26 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t세포 요법 |
| AU2022282266B2 (en) | 2021-05-24 | 2025-09-18 | Kite Pharma, Inc. | NKG2D-based chimeric antigen receptor |
| WO2022261061A1 (en) | 2021-06-08 | 2022-12-15 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
| US20230060292A1 (en) | 2021-07-26 | 2023-03-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| KR20240027077A (ko) | 2021-07-30 | 2024-02-29 | 카이트 파마 인코포레이티드 | 세포 요법-유도 독성의 모니터링 및 관리 |
| US20230303655A1 (en) | 2021-10-18 | 2023-09-28 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
| CN118742810A (zh) | 2022-02-15 | 2024-10-01 | 凯德药业股份有限公司 | 从免疫疗法预测不良事件 |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| JP2026508791A (ja) | 2022-10-28 | 2026-03-13 | カイト ファーマ インコーポレイテッド | 免疫療法の有効性及び永続的奏効の改善 |
| TWI882495B (zh) | 2022-10-28 | 2025-05-01 | 美商凱特製藥公司 | 用於將免疫療法最佳化之因素 |
| CN120917153A (zh) | 2023-03-17 | 2025-11-07 | 凯德药业股份有限公司 | 肿瘤微环境对免疫疗法疗效的影响 |
| US20250161361A1 (en) | 2023-11-01 | 2025-05-22 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| US20250290154A1 (en) | 2024-03-04 | 2025-09-18 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| TW202604957A (zh) | 2024-05-03 | 2026-02-01 | 美商凱特製藥公司 | 嵌合受體及其使用方法 |
| US20250382383A1 (en) | 2024-05-31 | 2025-12-18 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
| TW202607133A (zh) | 2024-07-08 | 2026-02-16 | 美商凱特製藥公司 | 用於對活細胞施加機械力以產生表型反應的系統及方法 |
| WO2026084968A1 (en) | 2024-10-14 | 2026-04-23 | Kite Pharma, Inc. | Biomarker based standards and methods of use |
| US20260224626A1 (en) | 2024-11-04 | 2026-08-06 | Kite Pharma, Inc. | Biomarkers related to immunotherapy efficacy |
| WO2026136591A1 (en) | 2024-12-18 | 2026-06-25 | Kite Pharma, Inc. | Jaml transmembrane and co-signaling domains for chimeric antigen receptors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112668T1 (el) | 2016-02-10 |
| PT2102331E (pt) | 2011-12-19 |
| JP2010514455A (ja) | 2010-05-06 |
| US20180036397A1 (en) | 2018-02-08 |
| SI2102331T1 (sl) | 2012-01-31 |
| EP2102331B1 (en) | 2011-08-31 |
| AU2008203730A1 (en) | 2008-07-10 |
| DK2102331T3 (da) | 2011-10-17 |
| GB0700058D0 (en) | 2007-02-07 |
| US10023839B2 (en) | 2018-07-17 |
| HRP20110899T1 (hr) | 2011-12-31 |
| ATE522600T1 (de) | 2011-09-15 |
| WO2008081035A1 (en) | 2008-07-10 |
| US20100092498A1 (en) | 2010-04-15 |
| EP2102331A1 (en) | 2009-09-23 |
| ES2372713T3 (es) | 2012-01-25 |
| AU2008203730B2 (en) | 2013-11-07 |
| JP5452231B2 (ja) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2102331T1 (sl) | Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic | |
| Zom et al. | Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates | |
| Vacchelli et al. | Trial watch: Peptide vaccines in cancer therapy | |
| Kumai et al. | Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses | |
| Melief et al. | Therapeutic cancer vaccines | |
| JP2010514455A5 (enExample) | ||
| Liu et al. | Telomerase in cancer immunotherapy | |
| EA202190587A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| Aranda et al. | Trial Watch: Peptide vaccines in cancer therapy | |
| BR112012023692A2 (pt) | imunoterapias contra vários tumores, incluindo câncer gastrointestinal e gástrico | |
| EA201071297A1 (ru) | Новые и действенные пептиды мнс ii класса, полученные из сурвивина | |
| MX338294B (es) | Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales. | |
| CL2019003423A1 (es) | Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| JP2015512866A5 (enExample) | ||
| CY1114912T1 (el) | Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου | |
| Arina et al. | Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1–resistant tumors leading to tumor eradication | |
| JP2018522880A5 (enExample) | ||
| Masuko et al. | Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy | |
| Yang et al. | HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma | |
| MX2020004757A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| US20170128555A9 (en) | Placental compositions for stimulation of immunity to pd-l1 | |
| Izgi et al. | Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice | |
| Melief | Peptide-based therapeutic cancer vaccines | |
| DE60033955D1 (de) | Melanoma impfstoff und seine herstellung und verwendung |